This document provides an outline of a presentation and is incomplete without the accompanying oral commentary and discussion. Conclusions and/ or potential strategies contained herein are NOT necessarily endorsed by Pfizer management. Any implied strategy herein would be subject to management, regulatory and legal review and approval before implementation.

India Corporate Social ResponsibilityIIT-Delhi Innovation & IP Program

India – A Powerhouseof Health careInnovationsWith the talent, infrastructure, academic and research capabilities and demand, India has the potential to become a powerhouse of health care innovations. Cost effective, easy to deploy and scalable solutions that address pressing healthcare challenges of the Country.

The Government of India has placed priority on innovation and entrepreneurship. The “National IPR Policy” aims to accelerate innovation, generation of intellectual property and awareness on IPR. “Startup India”, launched by the Hon’ble Prime Minister aims at fostering entrepreneurship and promoting innovation by creating an ecosystem that is conducive for the growth of Start-ups.

The Pfizer IIT-Delhi Innovation and IP Program is an industry-academia collaboration that is supported by the “Startup India” program. An endeavor that will contribute to the realization of these important ambitions for India.

Agenda

1. Companies Act CSR Provisions under Section 135 & Impact on Pfizer

2. Pfizer India CSRa. Purpose

b. Considerations for our focus areas

3. Pfizer IIT Delhi Innovation & IP program

1. Companies ActCSR Provisions under Section 135 & its impact on Pfizer India

Applicable to every company incorporated in India with either: ► Net worth of $80 mn (INR 500 crore) or more or;► Turnover of $160 mn (INR 1000 crore) or more or;► Net profit of $0.8 mn (INR 5 crore) or more.

*Average net profit to be calculated as per Section 198 of the Companies Act

Impact on Pfizer:

ØPfizer to spend ~ $ 1.2 mn on CSR activities for the FY 2016-17

ØPfizer spent ~ $ 1mn on CSR activities during FY 2015-16

Annual Required CSR Spend:► Every financial year, at least 2% of the * average

net profits made during the three preceding financial years

Schedule VII:► Indicates activities that can be undertaken by

a company to qualify under CSR

1

2

3

Purpose

Ø Promote access to quality health care

Ø Be partners to the Government and stakeholders on shared health care ambitions

Ø Nurture innovation

Ø Support community involvement of Pfizer colleagues

Ø Create goodwill for Pfizer in India

2. a. Pfizer India CSRPurpose

FOCUS AREAS (Pfizer will)

1. Encourage and support Indian innovation and Indian Intellectual Property with a focus on health care

2. Undertake awareness and access programs in partnership with NGOs , Govt and HCPs with a focus on Women and Child health

3. Support national /state programs and priorities with linkages to health care

4. Enlist employees as volunteers to support activities around health, sanitation and disease awareness

5. Participate in disaster relief activities

• CME programs

• Advisory Board meetings

• Patient Assistance Programs

• Capacity building of providers

• Disease awareness /detection programs

• Employee volunteering

• Disaster relief

What Pfizer already does

• Enhance value of innovation and intellectual property in India

• Advance salience of product portfolio

• Strengthen relationships with stakeholders – Govt and HCPs

Pfizer’s business priorities

• Preventive and positive health information / awareness

• Public-Private coalitions around disease awareness days

• Access to healthcare

• Public health & sanitation – Swachh Bharat

• Make in India / research and innovation in India/rural research

Areas of Govt priority in Health care and Innovation

• Promoting education & voc. skills/livelihood

• Promoting health care & sanitation

• Poverty alleviation/ Technology development

• Disaster relief / Women Empowerment

• Environmental sustainability

• Research & Studies/ Urban Slum development

Qualifying activities under Schedule VII

2. b. Pfizer India CSRConsiderations for focus areas

3. Pfizer India CSR Strategic Example:Pfizer IIT Delhi Innovation & IP Program

Pfizer – IIT DelhiInnovation & IP Program Is an incubation acceleratorco-created by Pfizer Ltd. and Foundation for Technology Transfer (FITT), IIT Delhi.

Two components of the programa. For innovators seeking support

to translate health care ideas into new business opportunities

b. For innovators who already have a proof of concept & looking for only IP related support

Program supports Health care InnovationsFunding, resources, expertise and infrastructure – that

allows innovators in India to bring their healthcare ideas to life and create patents

Initial unencumbered* funding commitment of upto $80,000 to each innovator to:

a. Provide innovators with residency for up to 2 years at the IIT Delhi Technology Incubator

b. Support incubation from birth stage, through prototyping to go-to-market including support for patent filing

c. Publish communication to invite proposals & raise awareness on the programme

Unencumbered* – Patents once obtained belong to innovators. Pfizer shall not have any claim on the patents nor own any equity in the resulting commercialization.

Pfizer through Pfizer IIT Delhi Innovation & IP Program provides

ProjectsselectedunderIP filingservices

Projects selected under resident incubation

Upto4 10

Upto

Per Year

Unencumbered funding of upto

Lakhs per Incubatee

Project status:

• 75 applications received from across the country within Phase 1 launch

• Project received visibility among key government stakeholders

• Selected the first set of innovators of Pfizer IIT-Delhi Innovation & IP Program through expert panel comprising of IIT-Delhi faculty, Pfizer nominees, IP experts, VCs & Industry veterans

Phase 2 Launch :• Phase 2 of the Program was launched in

September 2016

Project details

.

Projects Selectedfor Resident Incubation

Early Diagnosis ofTyphoid:A portable device for early stage typhoid diagnosis (within 6 hours), followed by antibiotic susceptibility information of S.typhi strain, to address the challenge of unavailability of timely and accurate diagnosis of typhoid fever.

A novel wearable device for protection fromthe respiratory hazards of air pollution:A novel wearable device, with unique air-purification technology for minimizing the inhalation of air-pollutants.Through its design, the device will ensure effectiveness, comfort and pleasing aesthetics to motivate users for regularusage.

Projects Selectedfor IP Filing Support

Multiboard − an Upper Extremity Workstation for Rural India:Designed for facilitating return of functionality and increased participation in stroke subjects.

Bioactive Nanofiber:To regenerate bone tissueengineering usingosteo-inductive and conductive scaffolds for use in orthopedic and craniofacial clinical practice.

Green Manufacturing of Pharmaceutical Intermediates:To convert the existing chemical process used in the manufacture of antibiotics into an enzymatic process which is cost effective greener and safer

The grantees Debayan Saha and Saurabh Singh being awarded at IIT-Delhi by IIT-Delhi Deputy Director - Prof. M. Balakrishnan & Pfizer MD- S.Sridhar

Project: Endo-nasal air purification device Project: Early cost-effective diagnosis and antibiotic susceptibility test of typhoid in 7hrs

Awarding the Grantees: Two under Resident Incubation

The grantees Dr. Shipa Dev, Dr. R. Rajkumar and Dr. Harpreet Sachdeva being awarded at IIT -Delhi

Project: Bioactive nanofiber (regenerate bone tissue)

Project: Multiboard (upper extremity workstation for rural India)

Project: Green manufacturing of pharmaceutical intermediaries

Awarding the Grantees: Three under IP Support

• Program showcased to the Prime Minister• Pfizer invited to participate in the launch of the

Startup India, Stand up India launch on Jan 16

Showcased to the Prime Minister

A Positive Partnershipto Support SharedAmbitions

The Pfizer IIT-Delhi Innovation and IP Program promotes, celebrates and rewards advancements in healthcare –innovations that are born and brought up in India for the benefit of patients, health care professionals and other targeted beneficiaries in the country. In doing so, the Program aligns with India’s stated priority of creating a vibrant innovation and entrepreneurship ecosystem.

From devices to diagnostics, mobile health to medicalinformatics – the Program will bring to life innovations thatare made in India and made for India.